Drug-induced immune hemolytic anemia may develop when an antibody-drug-red blood cell (RBC) interaction occurs (eg, with cephalosporins and with cefotetan) or when a drug (eg, fludarabine, methyldopa) alters the RBC membrane in a way that induces autoantibody production.